Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

J. Maurer, Matthew; H. Schwartz, Jeffrey; Gundapaneni, Balarama; Elliott, Perry; Merlini, Giampaolo; Waddington‐Cruz, Márcia; V. Kristen, Arnt; Grogan, Martha; Witteles, Ronald; Damy, Thibaud; Drachman, Brian; J. Shah, Sanjiv; Hanna, Mazen; P. Judge, Daniel; I. Barsdorf, Alexandra; M. Huber, Peter; A. Patterson, Terrell; Riley, Steve; Schumacher, Jennifer; Stewart, Michelle; B. Sultan, Marla; Rapezzi, Claudio

doi:10.1056/nejmoa1805689

Public

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Published in New England Journal of Medicine • Aug 27, 2018

Authors:

Matthew J. Maurer

Jeffrey H. Schwartz

Balarama Gundapaneni

Abstract

BACKGROUND: Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloid...

Subject

Transthyretin

Hazard ratio

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!